aTYR PHARMA (ATYR) Accumulated Expenses (2014 - 2026)

aTYR PHARMA (ATYR) has reported Accumulated Expenses for 13 consecutive years, with $6.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses fell 35.17% year-over-year to $6.7 million; the trailing twelve-month figure through Jun 2026 stood at $6.7 million (down 35.17% YoY), and the FY2025 full-year result was $9.8 million, up 4.25% from the prior year.
• Accumulated Expenses declined to $6.7 million in Q2 2026 per ATYR's latest filing, from $7.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.6 million in Q4 2023 and bottomed at $3.7 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $8.8 million across 5 years, with a median of $9.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses jumped 146.43% in 2022, then plunged 35.17% in 2026.
• Over 5 years, Accumulated Expenses stood at $9.9 million in 2022, then increased by 17.21% to $11.6 million in 2023, then retreated by 18.75% to $9.4 million in 2024, then rose by 4.25% to $9.8 million in 2025, then plunged by 31.67% to $6.7 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $6.7 million, $7.5 million, and $9.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.